Michael McFadden
Chief Executive Officer en ALPHA COGNITION INC. .
Fortuna: 167 242 $ al 31/03/2024
Perfil
Michael E.
McFadden currently works at Alpha Cognition, Inc., as Chief Executive Officer & Director from 2021.
Mr. McFadden also formerly worked at Amylin Pharmaceuticals, Inc., as Senior Director-Managed Markets from 2007 to 2010, Pharmacia Corp., as Director-State Purchasing from 2001 to 2003, Avanir Pharmaceuticals, Inc., as Senior Vice President-Commercial from 2015 to 2017, Urovant Sciences, Inc., as Chief Commercial Officer from 2018 to 2019, Urovant Sciences Ltd., as Chief Commercial Officer, and MPOWERHealth LLC, as Chief Commercial Officer.
Mr. McFadden received his undergraduate degree from the University of Louisiana at Monroe and undergraduate degree from Northeast Louisiana University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ALPHA COGNITION INC
0.33% | 19/01/2024 | 288 348 ( 0.33% ) | 167 242 $ | 31/03/2024 |
Cargos activos de Michael McFadden
| Empresas | Cargo | Inicio |
|---|---|---|
| ALPHA COGNITION INC. | Chief Executive Officer | 12/04/2021 |
Antiguos cargos conocidos de Michael McFadden.
| Empresas | Cargo | Fin |
|---|---|---|
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Corporate Officer/Principal | 01/11/2019 |
| UROVANT SCIENCES LTD. | Corporate Officer/Principal | 01/11/2019 |
| AVANIR PHARMACEUTICALS INC | Corporate Officer/Principal | 01/04/2017 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/04/2010 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | 01/01/2003 |
Formación de Michael McFadden.
| University of Louisiana at Monroe | Undergraduate Degree |
| Northeast Louisiana University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ALPHA COGNITION INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Michael McFadden
